Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An aggressive diffuse large B-cell lymphoma frequently arising in the setting of HIV infection and characterized by the presence of large neoplastic cells resembling B-immunoblasts which have the immunophenotypic profile of plasma cells. Sites of involvement include the oral cavity, sinonasal cavity, skin, soft tissues, gastrointestinal tract, and bone.
Biomarker and diagnostic research for plasmablastic lymphoma has been reported in the published literature.
No approved treatments are currently available for plasmablastic lymphoma. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for plasmablastic lymphoma, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for plasmablastic lymphoma. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
19 clinical trials registered, 9 recruiting. Interventions under study include drug therapy, biologic therapy, other interventions, and procedural interventions. Pipeline includes 4 PHASE2, 9 PHASE1, 1 EARLY_PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05544019](https://clinicaltrials.gov/study/NCT05544019) |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 7:12 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Designated
Exclusivity End |
|---|
Designation Status |
|---|
nanatinostat and valganciclovir | nanatinostat and valganciclovir | Viracta Therapeutics, Inc. | 2019 | — | Designated |
19 trials found
Study of SGR-1505 in Mature B-Cell Neoplasms |
PHASE1 |
Schrödinger, Inc. |
RECRUITING |
[NCT06781359](https://clinicaltrials.gov/study/NCT06781359) | Study on Plasmablastic Lymphoma Patients | — | Fondazione Italiana Linfomi - ETS | RECRUITING |
[NCT05663502](https://clinicaltrials.gov/study/NCT05663502) | Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers | — | AIDS Malignancy Consortium | RECRUITING |
[NCT07332507](https://clinicaltrials.gov/study/NCT07332507) | Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma | PHASE1 | National Cancer Institute (NCI) | RECRUITING |
[NCT05389423](https://clinicaltrials.gov/study/NCT05389423) | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | PHASE1 | National Cancer Institute (NCI) | RECRUITING |
112 publications have been identified in PubMed for plasmablastic lymphoma. Research spans Case Report / Case Series (56%), Review / Meta-Analysis (22%), and Epidemiology / Natural History (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 63 | 56% |
Research summaries | 25 | 22% |
Disease patterns and progression | 10 | 9% |
Laboratory research | 8 | 7% |
Other research | 3 | 3% |
Clinical study results | 2 | 2% |
Testing and diagnosis research | 1 | 1% |
Kaimi Y (2026). [PMID: 41689301](https://pubmed.ncbi.nlm.nih.gov/41689301/). *Hematological oncology*. [Diagnostic / Biomarker]
Candan O (2026). [PMID: 41522536](https://pubmed.ncbi.nlm.nih.gov/41522536/). *Indian J Hematol Blood Transfus*. [Other]
Al-Mashdali AF (2026). [PMID: 41542147](https://pubmed.ncbi.nlm.nih.gov/41542147/). *SAGE open medical case reports*. [Case Report / Case Series]
Repetto F (2026). [PMID: 41537415](https://pubmed.ncbi.nlm.nih.gov/41537415/). *Histopathology*. [Case Report / Case Series]
Kundu N (2026). [PMID: 40197599](https://pubmed.ncbi.nlm.nih.gov/40197599/). *Clin Nucl Med*. [Case Report / Case Series]
Pizzi M (2026). [PMID: 41817118](https://pubmed.ncbi.nlm.nih.gov/41817118/). *International journal of laboratory hematology*. [Basic Science / Preclinical]
Ishii K (2026). [PMID: 42219296](https://pubmed.ncbi.nlm.nih.gov/42219296/). *J Clin Exp Hematop*. [Case Report / Case Series]
Idrees FA (2026). [PMID: 42028537](https://pubmed.ncbi.nlm.nih.gov/42028537/). *Cureus*. [Case Report / Case Series]
Chen BJ (2026). [PMID: 42108217](https://pubmed.ncbi.nlm.nih.gov/42108217/). *J Cutan Pathol*. [Case Report / Case Series]
Cannova JM (2026). [PMID: 41771248](https://pubmed.ncbi.nlm.nih.gov/41771248/). *Journal of the National Comprehensive Cancer Network : JNCCN*. [Case Report / Case Series]
AI-curated news mentioning plasmablastic lymphoma
Updated May 10, 2026
A recent study highlights plasmablastic lymphoma presenting with multiple cutaneous nodules, which can be mistaken for primary cutaneous marginal zone lymphoma. This research contributes to the understanding of differential diagnoses in rare lymphomas.